Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO

Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she sees the road ahead for CNS clinical research.